IP Library Granted Patent US 10,071,147
Granted Patent B2
US 10,071,147 · App. 15/044,613 · Granted Sep 11, 2018

Method for enhancing immune response in the treatment of infectious and malignant diseases

Inventors: Keng-Li Lan (Taipei, TW); Yi-Sheng Shih (Taipei, TW); Keng-Hsin Lan (Taipei, TW)
Assignee: Taipei Veterans General Hospital
A61K39/0011A61K38/1774A61K45/06A61K2039/53A61K2039/55533A61K2039/55555A61K2039/572A61K2039/6031
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,071,147
App. No.
15/044,613
Granted
Sep 11, 2018
Kind
B2
Abstract

The present invention pertains to a new approach for the treatment of infectious and malignant diseases. The present invention provides new DNA and protein vaccines for the treatment of infectious and malignant diseases through enhancing immune response.

Claims (4)

1. A method for enhancing immune response in a subject under the treatment of an infectious or malignant disease, comprising administering the subject topically, subcutaneously or intramuscularly with a pharmaceutical composition comprising a DNA construct fused with a mammalian expression vector and a pharmaceutically acceptable carrier, wherein the DNA construct comprises (1) a polynucleotide sequence encoding Cytotoxic T-lymphocyte antigen-4 (CTLA-4) or a fragment thereof, and (2) programmed death-1 (PD-1) or a fragment thereof.

2. The method of claim 1 , wherein the subject is treated with an anti-infection or anti-cancer drug causing a stimulation of immune response in the subject.

3. The method of claim 1 , wherein the subject is under the treatment of a malignant disease.

4. The method of claim 1 , wherein the malignant disease is selected from the group consisting of metastatic melanoma, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, lymphoma, hormone refractory prostate cancer, ovarian cancer, acute myeloid leukemia, and non-small cell lung cancer.

Continuity (4)
Division 14079088 · Nov 13, 2013
Division 13532460 · Jun 25, 2012
Provisional Application 61500825 · Jun 24, 2011
Related Publication 20170028040A1 · Feb 2, 2017